Patents Assigned to Baylor
  • Combretastatin analogs with tubulin binding activity
    Patent number: 7429681
    Abstract: Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: September 30, 2008
    Assignee: Baylor University
    Inventors: Kevin G. Pinney, Madhavi Sriram
  • Therapeutic Applications of Activation of Human Antigen-Presenting Cells Through Dectin-1
    Publication number: 20080233140
    Abstract: The present invention includes compositions and methods for binding Dectin-1 on immune cells with anti-Dectin-1-specific antibodies or fragment thereof capable of activating the immune cells.
    Type: Application
    Filed: February 22, 2008
    Publication date: September 25, 2008
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Jacques F. Banchereau, SangKon Oh, Gerard Zurawski, Sandra Zurawski, Ling Ni
  • GENE EXPRESSION IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM CHILDREN WITH DIABETES
    Publication number: 20080227709
    Abstract: The present invention includes composition, methods and systems for detecting, evaluating, diagnosis, tracking and treating Type 1 Diabetes by determining the level of expression of one or more genes listed in Table 1 (e.g., interleukin-1? (IL1B), early growth response gene 3 (EGR3), and prostaglandin-endoperoxide synthase 2 (PTGS2)). The present invention also includes compositions and methods for treating a patient in need thereof with a composition having a therapeutically effective amount of one or more IL-1? antagonists sufficient to spare pancreatic beta cells, including an anti-IL-1? receptor and downstream activators.
    Type: Application
    Filed: March 12, 2008
    Publication date: September 18, 2008
    Applicants: BAYLOR RESEARCH INSTITUTE, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria Virginia Pascual, Jacques F. Banchereau, Damien J. Chaussabel, Ellen Kaizer, Perrin C. White
  • Transplantation of Glial Restricted Precursor-Derived Astrocytes for Promotion of Axon Growth
    Publication number: 20080226609
    Abstract: Provided herein are compositions and methods for the treatment of central nervous system (CNS) lesions comprising administration of glial restricted precursor (GRP) derived astrocytes (GDAs).
    Type: Application
    Filed: August 28, 2006
    Publication date: September 18, 2008
    Applicants: UNIVERSITY OF ROCHESTER, BAYLOR COLLEGE OF MEDICINE
    Inventors: Chris Proschel, Margot Mayer-Proschel, Jeannette Davies, Stephen Davies, Mark Noble
  • Method and machine for identifying a chemical compound related applications
    Publication number: 20080215253
    Abstract: The present invention is designed to efficiently calculate isotopic distribution in order to simulate mass spectra data for any chemical compound of interest. The simulated spectra considers the various isotopes of the compound based upon a probability calculation that takes into consideration the natural abundance of each isotope of individual elements of the compound. The probability calculation generates a relative probability associated with each isotope species of the subject compound. The simulated spectra are displayed on an x-y coordinate illustrating the calculated formula weight on the abscissa (x-axis) and the intensity of the specific species on the ordinate (y-axis). This theoretical data is then compared to experimental data taken from a mass spectrometer in order to identify the chemical compound at issue.
    Type: Application
    Filed: April 13, 2007
    Publication date: September 4, 2008
    Applicant: Baylor University
    Inventors: Florin Aniel Neacsu, David Eugene Pennington
  • Methods and compositions in breast cancer diagnosis and therapeutics
    Patent number: 7419785
    Abstract: The present invention is directed to compositions regarding a specific mutation in estrogen receptor alpha and their use as diagnostic markers in breast tissue, such as premalignant lesions, for the development of breast cancer. More specifically, cells of breast cancer whose nucleic acid comprises the estrogen receptor alpha mutation identify the breast cancer to be an invasive breast cancer.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: September 2, 2008
    Assignee: Baylor College of Medicine
    Inventors: Suzanne Fuqua, D. Craig Allred, Peter O'Connell, Torsten A. Hopp
  • MODIFIED PITUITARY GLAND DEVELOPMENT IN OFFSPRING FROM EXPECTANT MOTHER ANIMALS TREATED WITH GROWTH HORMONE RELEASING HORMONE THERAPY
    Publication number: 20080207543
    Abstract: The intramuscular electroporated injection of a protease-resistant growth hormone-releasing hormone (“GHRH”) cDNA into rat dams at 16 days of gestation resulted in the enhanced long-term growth of the FI offspring. The offspring were significantly heavier by one week of age and the difference was sustained to 10 weeks of age. Consistent with their augmented growth, plasma IGF-I concentration of the FI progeny was increased significantly. The pituitary gland of the offspring was significantly heavier, and contained an increased number of somatotropes (cells producing GH) and lactotrophs (prolactin-secreting cells), and is indicative of an alteration in cell lineages. These unique findings demonstrate that enhanced GHRH expression in pregnant dams can result in intergenerational growth promotion, by altering development of the pituitary gland in the offspring.
    Type: Application
    Filed: July 9, 2007
    Publication date: August 28, 2008
    Applicant: Baylor College of Medicine
    Inventors: Ruxandra Draghia-Akli, Amir Khan
  • Agents That Engage Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR)
    Publication number: 20080206262
    Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.
    Type: Application
    Filed: February 2, 2008
    Publication date: August 28, 2008
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Jacques F. Banchereau, SangKon Oh, Gerard Zurawski, Sandra Zurawski, Dapeng Li
  • Method and apparatus for desorption and ionization of analytes
    Patent number: 7413909
    Abstract: This invention relates generally to methods and apparatus for desorption and ionization of analytes for the purpose of subsequent scientific analysis by such methods, for example, as mass spectrometry or biosensors. More specifically, this invention relates to the field of mass spectrometry, especially to the type of matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry used to analyze macromolecules, such as proteins or biomolecules. Most specifically, this invention relates the sample probe geometry, sample probe composition, and sample probe surface chemistries that enable the selective capture and desorption of analytes, including intact macromolecules, directly from the probe surface into the gas (vapor) phase without added chemical matrix.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: August 19, 2008
    Assignee: Baylor College of Medicine
    Inventors: T. William Hutchens, Tai-Tung Yip
  • Induced activation in dendritic cell
    Patent number: 7404950
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: July 29, 2008
    Assignee: Baylor College of Medicine
    Inventors: David Spencer, Brent Hanks, Kevin Slawin
  • P38 MAPK pathway predicts endocrine-resistant growth of human breast cancer and provides a novel diagnostic and treatment target
    Patent number: 7402402
    Abstract: Acquired and de novo endocrine resistance are major clinical problems in the management of breast cancer patients. Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance. Furthermore, many of the resistant tumors actually appear to be stimulated by tamoxifen just as they are by estrogens. The present invention provides methods of predicting endocrine resistance comprising detecting the biological activity and/or expression of p38 MAPK and/or AIB1. The invention further provides methods of reducing, reversing, or preventing endocrine resistance comprising contacting a breast or prostate tumor with a p38 MAPK pathway inhibitor.
    Type: Grant
    Filed: April 29, 2007
    Date of Patent: July 22, 2008
    Assignee: Baylor College of Medicine
    Inventors: C. Kent Osborne, Rachel Schiff, Jiang Shou
  • Gene Expression Signatures in Blood Leukocytes Permit Differential Diagnosis of Acute Infections
    Publication number: 20080171323
    Abstract: The present invention includes compositions, systems and methods for the early detection and consistent determination of the extent, type and nature of a host immune response and the nature of the infectious disease using gene expression data.
    Type: Application
    Filed: August 10, 2007
    Publication date: July 17, 2008
    Applicants: BAYLOR RESEARCH INSTITUTE, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jacques F. Banchereau, Anna Karolina Palucka, Octavio Ramilo, Damien Chaussabel
  • Compositions and Methods for the Systemic Treatment of Arthritis
    Publication number: 20080161262
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Application
    Filed: October 26, 2007
    Publication date: July 3, 2008
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Jacques F. Banchereau, Maria Virginia Pascual
  • Compositions and Methods for the Systemic Treatment of Arthritis
    Publication number: 20080161424
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Application
    Filed: October 26, 2007
    Publication date: July 3, 2008
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Jacques F. Banchereau, Maria Virginia Pascual
  • Compositions and Methods for the Systemic Treatment of Arthritis
    Publication number: 20080160032
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Application
    Filed: October 26, 2007
    Publication date: July 3, 2008
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Jacques F. Banchereau, Maria Virginia Pascual
  • In Vivo Transformation of Pancreatic Acinar Cells into Insulin-Producing Cells
    Publication number: 20080145937
    Abstract: The present invention includes compositions and methods for transforming cells into glucose-responsive, insulin-production cells using a construct that expresses betacellulin and PDX1, e.g., transforming pancreatic acinar cells using one or more expression vectors that expressed betacellulin and PDX1 using ultrasound targeted microbubble destruction (UTMD).
    Type: Application
    Filed: September 21, 2007
    Publication date: June 19, 2008
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Paul A. Grayburn, Shuyuan Chen
  • Methods For Diagnosis And Monitoring Of Neurological Disease By Detection Of An Encephalotoxin
    Publication number: 20080138844
    Abstract: Encephalotoxin produced by activated mononuclear phagocytes is present in individuals having neurological disease including neurodegenerative and neuro-inflammatory diseases, such as Alzheimer's disease (AD), HIV-1-associated dementia (HAD), Creutzfeldt-Jakob disease, Mild Cognitive Impairment, prion disease, minor cognitive/motor dysfunction, acute stroke, acute trauma, or neuro-AIDS. Biochemical detection of encephalotoxin according to the methods of the invention will allow diagnosis of neurological disease in early, presymptomatic stages, thereby allowing early intervention in disease progression as well as identification of subjects or populations at risk for developing neurodegenerative disease. The methods of the invention also provide a mechanism for monitoring progression and treatment of neurological disease.
    Type: Application
    Filed: January 8, 2008
    Publication date: June 12, 2008
    Applicant: Baylor College Of Medicine
    Inventor: Dana J. Giulian
  • Functionalized stilbene derivatives as improved vascular targeting agents
    Patent number: 7384925
    Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.
    Type: Grant
    Filed: July 18, 2005
    Date of Patent: June 10, 2008
    Assignees: OXiGENE, Inc., Baylor University
    Inventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
  • Nutrient Sensor
    Publication number: 20080132571
    Abstract: The present invention includes compositions and methods for treating the effects of catabolism in a patient by providing the patient with an amount of an odd-chain fatty acid sufficient to increase the intracellular ratio of AMP to ATP and reduce the activity of AMPK.
    Type: Application
    Filed: September 26, 2007
    Publication date: June 5, 2008
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventor: Charles R. Roe
  • Dendritic Cells Loaded with Heat Shocked Melanoma Cell Bodies
    Publication number: 20080112924
    Abstract: The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 15, 2008
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Anna Karolina Palucka, Jacques F. Banchereau